» Articles » PMID: 37340382

Global, Regional and National Availability of Essential Medicines for Children, 2009-2020: a Systematic Review and Meta-analysis

Overview
Publisher Biomed Central
Specialty Public Health
Date 2023 Jun 20
PMID 37340382
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Access to essential medicines is a vital component of universal health coverage. The low availability of essential medicines for children (EMC) has led the World Health Organization (WHO) to issue a number of resolutions calling on member states on its improvement. But its global progress has been unclear. We aimed to systematically evaluate the progress of availability of EMC over the past decade across economic regions and countries.

Methods: We searched eight databases from inception to December 2021 and reference lists to identify included studies. Two reviewers independently conducted literature screening, data extraction and quality evaluation. This study was registered with PROSPERO, CRD42022314003.

Results: Overall, 22 cross-sectional studies covering 17 countries, 4 income groups were included. Globally, the average availability rates of EMC were 39.0% (95%CI: 35.5-42.5%) in 2009-2015 and 43.1% (95%CI: 40.1-46.2%) in 2016-2020. Based on the World Bank classification of economic regions, income was not proportional to availability. Nationally, the availability rate of EMC was reasonable and high (> 50%) in only 4 countries, and low or very low for the rest 13 countries. The availability rates of EMC in primary healthcare centers had increased, while that for other levels of hospitals slightly declined. The availability of original medicines decreased while that of generic medicines was stable. All drug categories had not achieved the high availability rate.

Conclusion: The availability rate of EMC was low globally, with slight increase in the last decade. Continuous monitoring and timely reporting of the availability of EMC are also needed to facilitate targets setting and inform relevant policy making.

Citing Articles

The availability of essential medicines in primary health centres in Indonesia: achievements and challenges across the archipelago.

Fanda R, Probandari A, Yuniar Y, Hendarwan H, Trisnantoro L, Jongeneel N Lancet Reg Health Southeast Asia. 2024; 22:100345.

PMID: 38482146 PMC: 10934320. DOI: 10.1016/j.lansea.2023.100345.

References
1.
Mehta P, Wiernikowski J, Petrilli J, Barr R . Essential medicines for pediatric oncology in developing countries. Pediatr Blood Cancer. 2013; 60(5):889-91. DOI: 10.1002/pbc.24476. View

2.
Dorj G, Sunderland B, Sanjjav T, Dorj G, Gendenragchaa B . Availability, affordability and costs of pediatric medicines in Mongolia. BMC Pediatr. 2018; 18(1):149. PMC: 5932849. DOI: 10.1186/s12887-018-1123-x. View

3.
Vassal G, Kozhaeva O, Griskjane S, Arnold F, Nysom K, Basset L . Access to essential anticancer medicines for children and adolescents in Europe. Ann Oncol. 2021; 32(4):560-568. DOI: 10.1016/j.annonc.2020.12.015. View

4.
Chen Z, Li S, Zeng L, Liu Y, Zhang M, Choonara I . Accessibility of Medicines for Children: A Systematic Review. Front Pharmacol. 2021; 12:691606. PMC: 8375435. DOI: 10.3389/fphar.2021.691606. View

5.
Robertson J, Magrini N, Barr R, Forte G, Ondari C . Medicines for cancers in children: The WHO model for selection of essential medicines. Pediatr Blood Cancer. 2015; 62(10):1689-93. PMC: 5132122. DOI: 10.1002/pbc.25564. View